Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,074 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S. Castro M, et al. Among authors: murphy k. Lancet Respir Med. 2015 May;3(5):355-66. doi: 10.1016/S2213-2600(15)00042-9. Epub 2015 Feb 23. Lancet Respir Med. 2015. PMID: 25736990 Clinical Trial.
Taking Aim at Asthma Around the World: Global Results of the Asthma Insight and Management Survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United States.
Nathan RA, Thompson PJ, Price D, Fabbri LM, Salvi S, González-Díaz S, Maspero JF, Moreno-Cantu JJ, Fish JE, Murphy K. Nathan RA, et al. Among authors: murphy k. J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):734-42.e5. doi: 10.1016/j.jaip.2015.04.013. Epub 2015 Jun 23. J Allergy Clin Immunol Pract. 2015. PMID: 26116167
Early decreases in blood eosinophil levels with reslizumab.
Chanez P, McDonald M, Garin M, Murphy K. Chanez P, et al. Among authors: murphy k. J Allergy Clin Immunol. 2019 Apr;143(4):1653-1655. doi: 10.1016/j.jaci.2018.12.997. Epub 2019 Jan 14. J Allergy Clin Immunol. 2019. PMID: 30654046 Clinical Trial. No abstract available.
Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma.
Nair P, Bardin P, Humbert M, Murphy KR, Hickey L, Garin M, Vanlandingham R, Chanez P. Nair P, et al. J Allergy Clin Immunol Pract. 2020 Feb;8(2):555-564. doi: 10.1016/j.jaip.2019.09.036. Epub 2019 Oct 15. J Allergy Clin Immunol Pract. 2020. PMID: 31626990 Free article. Clinical Trial.
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, Humbert M, Castro M, Marsteller DA, McElhattan J, Hickey L, Garin M, Vanlandingham R, Brusselle G. Bernstein JA, et al. Among authors: murphy k. Lancet Respir Med. 2020 May;8(5):461-474. doi: 10.1016/S2213-2600(19)30372-8. Epub 2020 Feb 14. Lancet Respir Med. 2020. PMID: 32066536 Clinical Trial.
The variability of asthma.
Murphy KR, Berger WE. Murphy KR, et al. Curr Med Res Opin. 2005 Oct;21(10):1519-26. doi: 10.1185/030079905X65358. Curr Med Res Opin. 2005. PMID: 16238891 Review.
4,074 results